Novartis Signs License Agreement with MorphoSys to Develop and Commercialise Preclinical Inhibitors for Cancer
By Ashish Tripathi
Pharma Deals Review: Vol 2022 Issue 12 (Table of Contents)
Published: 21 Dec-2022
DOI: 10.3833/pdr.v2022.i12.2755 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to bolster its preclinical pipeline, Novartis has entered into a licensing agreement with MorphoSys for US$23 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS